The Hydrus Microstent is a revolutionary canal-based minimally invasive glaucoma surgery (MIGS) device for adult patients with mild to moderate primary open-angle glaucoma undergoing cataract surgery. The device is a highly flexible, biocompatible 8 mm long microstent, made out of an alloy called nitinol and is delivered ab interno into the trabecular meshwork and Schlemm’s canal. Known for its flexibility and “shape memory”, nitinol is commonly used in medical devices and implanted in different areas of the body including blood vessels and bones.1
Rounded distal tip for a smooth passage into Schlemm’s canal
Open scaffold design provides outflow pathways for aqueous
Aqueous inlet facilitating flow from anterior chamber to Schlemm’s canal
Hydrus Microstent has been clinically proven through multiple prospective, randomized, controlled studies to consistently reduce medication usage and intraocular pressure (IOP) through a unique Tri-Modal mechanism of action:2
The only MIGS implant to span approximately 90° of Schlemm’s canal, ensuring consistent access to collector channels in the nasal region.
The first MIGS device to precisely dilate and scaffold Schlemm’s canal, gently expanding the cross sectional area without obstruction outflow access to collector channel ostia.3
The Hydrus Microstent bypasses the trabecular meshwork to restore flow of aqueous from the anterior chamber through the inlet of the microstent into Schlemm’s canal.